Chris Tyler

Chris Tyler

Chris Tyler, a Wall Street veteran of more than 20 years, began his career in the financial markets working on the trading floor of the AMEX in New York as an equity option market maker at Interactive Brokers’ floor trading unit Timber Hill LLC.

After moving to San Francisco to make markets on the P-Coast exchange during the dot-com craze and spending nearly a decade working in names like Philip Morris, Seagate and Compaq, Chris hung up his smock and trading badge, but not his passion for options and the markets.

Since exiting the floor, and for the better part of the past dozen years, Chris has worked as an option and market strategist, writing analyses for Trading Markets, Charles Schwab subsidiary Optionetics and as a featured columnist at Investor’s Business Daily.

Aside from offering his trading insights at InvestorPlace.com, Chris is currently studying for his Accredited Portfolio Management Advisor (APMA) designation, manages investments for closely held accounts and offers his services as an investment strategist to GLJ Advisors, a CA based RIA.

Chris, his wife and blue heeler live in the Pacific NW. And if you can’t follow him around in your own VW Vanagon or Westfalia, feel free to follow him on Twitter via @Options_CAT.

Recent Articles

Keep Calm And Don’t Trade TTD Stock Just Yet

Longer-term TTD stock has a lot going for it, but as a growth stock upstart a less-fit market environment demands patience rather than purchasing.

3 Diverse and Critical Stocks to Watch For a Market Bottom

These three will undoubtedly become stocks to buy. For right now they're critical stocks to watch as the market attempts to locate a bottom.

Why TSLA Stock Is Revving Higher for Fast Money Bulls

Whether Tesla can fulfill some big picture views of $7000 or more remains to be seen. But what’s being shown on today’s TSLA stock chart looks awfully good

Why GE Stock Is Now a ‘Buy, Buy, Buy!’

Applaud the government’s latest efforts to combat an ill market, but more importantly appreciate a big-time opportunity in GE stock

Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio?

Inovio Pharmaceuticals continues to rally on COVID-19 vaccine hopes, but overbought conditions and key challenges still make INO stock a risky proposition.